NeuroSense to Host Investor Webinar on December 8, 2025
PR Newswire —
Business, regulatory and clinical updates will be provided CAMBRIDGE, Mass., Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today...